AcouSort AB (4SA) AI Stock Analysis

AcouSort AB

(Frankfurt:4SA)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Debt-free balance sheetNo reported debt materially lowers solvency and refinancing pressure, giving AcouSort greater flexibility while it develops and commercializes its acoustofluidic modules. This conservative financing profile can help preserve strategic options through the next several quarters despite current losses.

Negative Factors

Deeply negative profitabilityNegative gross profit and substantial operating and net losses show that AcouSort has not yet established a stable, scalable profit model. Persistent losses can limit internal reinvestment capacity and make future performance highly dependent on achieving meaningful margin improvement.

AcouSort AB (4SA) vs. iShares MSCI Germany ETF (EWG)

Market Cap: EUR 6.22M
Dividend Yield: ―
Average Volume (3M): ―
Price to Earnings (P/E): -6.2
Beta (1Y): -0.00
Revenue Growth: 48.05%
EPS Growth: 33.77%
Country: Germany
Employees: 11
Sector: Healthcare
Sector Strength: 51
Industry: Medical - Distribution

AcouSort AB Business Overview & Revenue Model

Company Description

AcouSort AB (publ), a technology company, develops components and instruments used in the diagnostics, analytics, and cell therapy processing markets. It offers AcouTrap, a benchtop research instrument for sample preparation of cells, extracellular v...

AcouSort AB Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

DE:4SA against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SE:CEVI	83Outperform	SEK 4.67B	33.84	15.23%	1.41%	1.95%	-8.91%
SE:FLUI	55Neutral	SEK 38.33M	13.65	21.37%	―	837.37%	―
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
SE:BICO	48Neutral	SEK 1.73B	-2.06	-49.84%	―	-15.45%	-164.23%
SE:IMMNOV	45Neutral	SEK 33.70M	-0.30	-279.07%	―	31.66%	79.68%
SE:QLINEA	43Neutral	SEK 282.34M	-1.13	-48.10%	―	33.26%	90.73%

* Healthcare Sector Average

Performance Comparison

DE:4SA and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
DE:4SA	AcouSort AB	0.27	0.09	45.99%
SE:BICO	BICO Group AB Class B	24.45	0.55	2.30%
SE:CEVI	CellaVision AB	195.60	22.06	12.71%
SE:IMMNOV	Immunovia AB	0.05	-0.26	-83.92%
SE:QLINEA	Q-linea AB	14.90	-10.33	-40.94%
SE:FLUI	Fluicell AB	27.90	15.10	117.97%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

AcouSort AB AI Stock Analysis